<info type="ChemicalEntity">Estrogen</info> prevents <info type="ChemicalEntity">cholesteryl ester</info> accumulation in <info type="OrganismTaxon">macrophages</info> induced by the <info type="ChemicalEntity">HIV protease inhibitor ritonavir</info>.

Individuals with <info type="DiseaseOrPhenotypicFeature">HIV</info> can now live long lives with drug therapy that often includes <info type="ChemicalEntity">protease inhibitors</info> such as <info type="ChemicalEntity">ritonavir</info>. Many patients, however, develop negative long-term side effects such as <info type="DiseaseOrPhenotypicFeature">premature atherosclerosis</info>. We have previously demonstrated that <info type="ChemicalEntity">ritonavir</info> treatment increases <info type="DiseaseOrPhenotypicFeature">atherosclerotic lesion</info> formation in <info type="OrganismTaxon">male mice</info> to a greater extent than in <info type="OrganismTaxon">female mice</info>. Furthermore, peripheral blood <info type="GeneOrGeneProduct">monocytes</info> isolated from <info type="ChemicalEntity">ritonavir</info>-treated <info type="OrganismTaxon">females</info> had less <info type="ChemicalEntity">cholesteryl ester</info> accumulation. In the present study, we have investigated the molecular mechanisms by which <info type="ChemicalEntity">female hormones</info> influence <info type="ChemicalEntity">cholesterol</info> metabolism in <info type="OrganismTaxon">macrophages</info> in response to the <info type="ChemicalEntity">HIV protease inhibitor ritonavir</info>. We have utilized the <info type="OrganismTaxon">human</info> <info type="CellLine">monocyte cell line</info>, <info type="CellLine">THP-1</info> as a model to address this question. Briefly, cells were differentiated for 72 h with 100 nM <info type="ChemicalEntity">PMA</info> to obtain a <info type="DiseaseOrPhenotypicFeature">macrophage-like phenotype</info> in the presence or absence of 1 nM <info type="ChemicalEntity">17beta-estradiol (E2)</info>, 100 nM <info type="ChemicalEntity">progesterone</info> or vehicle (0.01% <info type="ChemicalEntity">ethanol</info>). Cells were then treated with 30 ng/ml <info type="ChemicalEntity">ritonavir</info> or vehicle in the presence of aggregated <info type="ChemicalEntity">LDL</info> for 24 h. Cell extracts were harvested, and <info type="ChemicalEntity">lipid</info> or total <info type="GeneOrGeneProduct">RNA</info> was isolated. <info type="ChemicalEntity">E2</info> decreased the accumulation of <info type="ChemicalEntity">cholesteryl esters</info> in <info type="OrganismTaxon">macrophages</info> following <info type="ChemicalEntity">ritonavir</info> treatment. <info type="ChemicalEntity">Ritonavir</info> increased the expression of the <info type="GeneOrGeneProduct">scavenger receptor</info>, <info type="GeneOrGeneProduct">CD36 mRNA</info>, responsible for the uptake of <info type="ChemicalEntity">LDL</info>. Additionally, <info type="ChemicalEntity">ritonavir</info> treatment selectively increased the relative levels of <info type="GeneOrGeneProduct">PPARgamma mRNA</info>, a transcription factor responsible for the regulation of <info type="GeneOrGeneProduct">CD36 mRNA</info> expression. Treatment with <info type="ChemicalEntity">E2</info>, however, failed to prevent these increases at the <info type="GeneOrGeneProduct">mRNA</info> level. <info type="ChemicalEntity">E2</info> did, however, significantly suppress <info type="GeneOrGeneProduct">CD36 protein</info> levels as measured by fluorescent <info type="GeneOrGeneProduct">immunocytochemistry</info>. This data suggests that <info type="ChemicalEntity">E2</info> modifies the expression of <info type="GeneOrGeneProduct">CD36</info> at the level of <info type="GeneOrGeneProduct">protein</info> expression in <info type="OrganismTaxon">monocyte-derived macrophages</info> resulting in reduced <info type="ChemicalEntity">cholesteryl ester</info> accumulation following <info type="ChemicalEntity">ritonavir</info> treatment.